Further Genomic Analysis May Expand the Pancreatic Cancer Field

Commentary
Video

It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.

In a conversation with CancerNetwork® during Pancreatic Cancer Awareness Month, Tanios S. Bekaii-Saab, MD, highlighted the importance of profiling pancreatic cancer tumors for genomic analysis among all eligible patients to help inform treatment decision-making in the field.

According to Bekaii-Saab, David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research, Chair and Consultant in the Division of Hematology and Medical Oncology at Mayo Clinic in Arizona, and Co-Leader of Advanced Clinical and Translational Science at Mayo Clinic Cancer Center, there are several new targeted agents that are advancing through clinical trials or being developed for use in the clinic. Consequently, it may be crucial to test for markers such as BRAF V600E mutations, NRG1 fusions, and other RAS mutations to better tailor treatment strategies for each individual patient. Additionally, Bekaii-Saab emphasized the use of testing to screen for inherited germline mutations that may be linked to a patient’s disease.

Transcript:

It’s very important to ensure that every single patient with pancreatic cancer—every tumor of every patient with pancreatic cancer—needs to be profiled for genomic analysis. Why? Because now we have all these targeted agents that are either making their way into clinical trials or hopefully making their ways into the clinic. [For example,] we’ve talked about BRAF V600E mutations. We’ve talked about KRAS G12C mutations.

We’re seeing so many targets that are now emerging in pancreatic cancer that, in some ways, it would be relative malpractice not to profile all these tumors. [We must] make sure that we’re going to find every single one of them: microsatellite instability–high [MSI-H], RAS mutations....BRAF V600E mutations, NRG1 fusions, you name it. This is expanding the field.

The message needs to be clear that for every single patient with pancreatic cancer, we need to have an assessment of inherited mutations. [This includes] germline mutations because [approximately] 5% to 10% of those patients will have some alterations that may link to the cancer. [This also includes] genomic analysis.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Related Content